Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs
05 1월 2022 - 6:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will present data on broadly neutralizing SARS-CoV-2
antibodies discovered by the company at the upcoming Keystone
Symposia Conference: Antibodies as Drugs, being held January 30 –
February 2, 2022 both in Keystone, Colo. and virtually.
Details are as follows:
- Abstract title: Broadly neutralizing SARS-CoV-2 antibodies
discovered in multiple patients target the Receptor Binding
Domain
- Poster Session 1: January 31, 10:00 a.m. - 7:30 p.m. ET
The abstract is currently available to registered
attendees on the Keystone Symposia website, and the poster
presentation will be posted to the company’s website on Monday,
January 31st at 10am ET.
Atreca applied its IRC® technology to generate
antibodies from patients infected with the original SARS-CoV-2
virus. IgG variable region sequences were generated from
plasmablasts originating from 12 patients, with 1-4 sample
timepoints provided during acute infection. Neutralizing activity
was assessed against the original SARS-CoV-2 virus and a panel of
seven SARS-CoV-2 variants.
Twenty-four of 209 SARS-CoV-2-binding antibodies
had neutralizing activity against replication competent SARS-CoV-2
in an initial screen. Two antibodies originating from distinct B
cell lineages and from different donors neutralized all seven of
the tested SARS-CoV-2 variants. Using these two broadly
neutralizing antibodies, the Atreca SARS-CoV-2 dataset was queried
for convergent sequences. These efforts resulted in the discovery
of two new antibodies from a third donor. Both antibodies also
neutralized the same panel of seven SARS-CoV-2 variants, and one
demonstrated notable potency. All four pan-neutralizing antibodies
exhibit favorable developability properties, including high melting
temperatures and low polyreactivity.
“While a number of therapeutic antibodies targeting
SARS-CoV-2 have been developed, they often have limited efficacy
against emerging viral variants,” said Tito A. Serafini, Ph.D.,
Chief Strategy Officer of Atreca. “We believe the discovery of
broadly neutralizing antibodies with favorable developability
profiles will continue to be important for treating COVID-19, and
that these data show the ability of our antibodies to target
emerging variants.”
About Atreca, Inc. Atreca is a
biopharmaceutical company developing novel antibody-based
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumors. These antibodies provide
the basis for first-in-class therapeutic candidates, such as our
lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements regarding
our plans, objectives, representations, and contentions and
typically are identified by use of terms such as "believe,”
“continue,” and similar words. These statements include those
regarding the favorable developability properties of our four
pan-neutralizing antibodies, the limited efficacy of current
therapeutic antibodies targeting SARS-CoV-2 against emerging viral
variants, the continued importance of the discovery of broadly
neutralizing antibodies with favorable developability profiles for
treating COVID-19, the potential ability of our antibodies to
target emerging variants, the development of ATRC-101 and our
preclinical, clinical and regulatory plans and the timing thereof.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our
research and development programs, preclinical studies, clinical
trials, regulatory submissions, and other matters that are
described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website
at www.sec.gov, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of our most recently filed annual
report on Form 10-K and quarterly report on Form 10-Q. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release,
and we undertake no obligation to update any forward-looking
statement in this press release, except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray, 650-779-9251, ext.
251agray@atreca.com
Media:Julia Fuller,
858-692-2001julia@fordhutmanmedia.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024